Lates News

According to a brief AI news from Meijing, Guojin Securities released a research report on April 29, giving Yifeng Pharmacy (603939.SH) a buy rating. The main reasons for the rating include: 1) steady expansion, timely optimization of stores, and temporary slowdown in revenue growth; 2) maintaining high operational quality by simultaneously reducing costs and increasing efficiency. (Daily Economic News)